靶点- |
|
|
|
|
|
最高研发阶段批准上市 |
|
首次获批日期2005-10-03 |
A Phase II open-label pilot study to evaluate the safety and efficacy of subcutaneously administered ELX-02 in patients with Alport syndrome with Col4A5 and Col4A3/4 nonsense mutation
A Randomized, Open-Label Phase II/III Study With Dendritic Cells Loaded With Allogeneic Tumour Cell Lysate (PheraLys) in Subjects With Mesothelioma as Maintenance Treatment (MesoPher) After Chemotherapy
This study is to evaluate the overall survival (OS) rate (determined from the time of randomization in the study) of subjects who receive dendritic cell immunotherapy with MesoPher plus best supportive care (BSC) compared to BSC alone.
100 项与 TMC Pharma Services Ltd. 相关的临床结果
0 项与 TMC Pharma Services Ltd. 相关的专利(医药)
100 项与 TMC Pharma Services Ltd. 相关的药物交易
100 项与 TMC Pharma Services Ltd. 相关的转化医学